GlassScriptPhysician profile
Ian R Martinez
NPI 1376734962
$4,653.01
in general payments reported to CMS, 2019-2025
28 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $375 · 2021: $534 · 2022: $546 · 2023: $313 · 2024: $1,019 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,409.45 | 2019-2025 | |
| Janssen Biotech, INC. | $597.62 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $500.30 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $419.12 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $354.11 | 2019-2025 | Xifaxan, Plenvu |
| Madrigal Pharmaceuticals | $227.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $214.71 | 2019-2025 | |
| Ardelyx, INC. | $130.08 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $89.71 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $85.44 | 2022-2024 | Dupixent |
| Evoke Pharma, INC. | $74.97 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $72.19 | 2019-2020 | |
| Lilly USA, LLC | $53.61 | 2025 | Omvoh |
| Celgene Corporation | $48.93 | 2021-2022 | |
| Braintree Laboratories, INC. | $39.35 | 2021-2023 | Suflave |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $38.25 | 2024-2025 | Pancreaze, Qsymia |
| Gilead Sciences, INC. | $35.11 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $31.91 | 2021 | |
| Allergan, INC. | $29.96 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $29.79 | 2025 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $29.68 | 2025 | Givlaari |
| Novo Nordisk INC | $28.54 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $25.58 | 2025 | Zenpep |
| Boston Scientific Corporation | $21.33 | 2019 | |
| Genzyme Corporation | $19.83 | 2025 | |
| Echosens North America, INC. | $19.02 | 2022 | |
| Conmed Corporation | $14.09 | 2019 | |
| Shire North American Group INC | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.